Stock Scorecard



Stock Summary for Myriad Genetics Inc (MYGN) - $15.30 as of 11/20/2024 8:28:35 PM EST

Total Score

9 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for MYGN

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for MYGN

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for MYGN

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for MYGN

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for MYGN (32 out of 90)

Stock Price Rating (Max of 10) 6
Historical Stock Price Rating (Max of 10) 6
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 4
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 4
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 6
Price to Earnings (Max of 10) 0

Latest News for for MYGN

Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina's Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2 - Illumina ( NASDAQ:ILMN ) , Myriad Genetics ( NASDAQ:MYGN ) 11/20/2024 9:30:00 PM
Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina's Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2 11/20/2024 9:30:00 PM
SINTX Technologies Appoints Gregg R. Honigblum as Chief Strategy Officer 11/19/2024 11:00:00 AM
MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm - Myriad Genetics ( NASDAQ:MYGN ) 11/17/2024 9:00:00 PM
MYGN Stock Might Gain From SneakPeek Availability in Retail Stores 11/14/2024 1:36:00 PM
Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch 11/13/2024 1:00:00 PM
PACB Stock Falls Despite Q3 Earnings Beat, Revenues Decline Y/Y 11/8/2024 3:10:00 PM
MYGN Beats on Q3 Earnings and Revenues, Raises '24 EPS View 11/8/2024 1:28:00 PM
Myriad Genetics ( MYGN ) Q3 Earnings and Revenues Surpass Estimates 11/7/2024 11:00:00 PM
BIIB vs. MYGN: Which Stock Is the Better Value Option? 11/6/2024 4:40:00 PM

Financial Details for MYGN

Company Overview

Ticker MYGN
Company Name Myriad Genetics Inc
Country USA
Description Myriad Genetics, Inc., a molecular diagnostics company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company is headquartered in Salt Lake City, Utah.
Sector Name LIFE SCIENCES
Industry Name IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Most Recent Quarter 6/30/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 15.30
Price 4 Years Ago 19.77
Last Day Price Updated 11/20/2024 8:28:35 PM EST
Last Day Volume 687,113
Average Daily Volume 906,070
52-Week High 29.30
52-Week Low 14.91
Last Price to 52 Week Low 2.62%

Valuation Measures

Trailing PE N/A
Industry PE 44.80
Sector PE 40.32
5-Year Average PE 30.66
Free Cash Flow Ratio 13.91
Industry Free Cash Flow Ratio 41.60
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 1.90
Total Cash Per Share 1.10
Book Value Per Share Most Recent Quarter 8.04
Price to Book Ratio 1.90
Industry Price to Book Ratio 9.11
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 1.69
Industry Price to Sales Ratio Twelve Trailing Months 8.48
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 4
Analyst Strong Buy Ratings 3

Share Statistics

Total Shares Outstanding 91,035,000
Market Capitalization 1,392,835,500
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 3.63%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -135.09%
Reported EPS 12 Trailing Months -1.28
Reported EPS Past Year 0.10
Reported EPS Prior Year -0.28
Net Income Twelve Trailing Months -116,000,000
Net Income Past Year -263,300,000
Net Income Prior Year -112,000,000
Quarterly Revenue Growth YOY 11.20%
5-Year Revenue Growth -0.64%
Operating Margin Twelve Trailing Months -0.08

Balance Sheet

Total Cash Most Recent Quarter 99,900,000
Total Cash Past Year 97,300,000
Total Cash Prior Year 140,900,000
Net Cash Position Most Recent Quarter 61,100,000
Net Cash Position Past Year 58,800,000
Long Term Debt Past Year 38,500,000
Long Term Debt Prior Year 38,500,000
Total Debt Most Recent Quarter 38,800,000
Equity to Debt Ratio Past Year 0.95
Equity to Debt Ratio Most Recent Quarter 0.95
Total Stockholder Equity Past Year 740,500,000
Total Stockholder Equity Prior Year 783,200,000
Total Stockholder Equity Most Recent Quarter 731,700,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -107,300,000
Free Cash Flow Per Share Twelve Trailing Months -1.18
Free Cash Flow Past Year -184,200,000
Free Cash Flow Prior Year -151,600,000

Options

Put/Call Ratio 0.01
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -2.21
MACD Signal -1.93
20-Day Bollinger Lower Band 17.45
20-Day Bollinger Middle Band 24.97
20-Day Bollinger Upper Band 32.50
Beta 1.94
RSI 21.81
50-Day SMA 22.88
150-Day SMA 21.54
200-Day SMA 23.69

System

Modified 11/19/2024 7:39:10 AM EST